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Substantial advances have been made in understanding the biology of multiple myeloma (MM) through the study of the
bone marrow (BM) microenvironment. Indeed, the BM niche appears to play an important role in diﬀerentiation, migration,
proliferation, survival, and drug resistance of the malignant plasma cells. The BM niche is composed of a cellular compartment
(stromal cells, osteoblasts, osteoclasts, endothelial cells, and immune cells) and a noncellular compartment including the
extracellular matrix (ECM) and the liquid milieu (cytokines, growth factors, and chemokines). In this paper we discuss how the
interaction between the malignant plasma cell and the BM microenvironment allowed myeloma progression through cell homing
and the new concept of premetastatic niche.
1.Introduction
Multiple myeloma (MM) is a hematologic malignancy char-
acterized by the accumulation of monoclonal plasma cells
in the bone marrow (BM), over 10% by deﬁnition [1]. In
almost all cases, MM is preceded by a premalignant disease
well known as monoclonal gammopathy of undetermined
signiﬁcance (MGUS) [2, 3]. MGUS aﬀects 2% of the
populationabovetheageof50anditprogressestoovertMM
at a rate of 1% per year [4].
The biologic transition from normal plasma cells to
MGUS and SMM to MM consists of many oncogenic events.
A ne a r l ye v e n td e s c r i b e di nM G U Sa sw e l la sM Mi st h e
dysregulation of a cyclin D gene [5]. Secondary transloca-
tions, sometimes involving an Ig locus, can occur at any
stage of plasma cell dyscrasia. Activating mutations of NRAS
and KRAS are each present in about 15% of multiple
myeloma tumors. Constitutive activation of the nuclear
factor κB( N F κB) pathway is mediated by mutations in some
tumors during progression. In addition to these oncogenic
events, the tumor cells are strongly dependent on the bone
marrow microenvironment [6]. Substantial advances have
been made in understanding the biology of MM through
the study of the BM microenvironment. Indeed, the BM
niche appears to play an important role in diﬀerentiation,
migration, proliferation, survival, and drug resistance of the
malignant plasma cells providing the preclinical evidences
for targeting MM cells and bone marrow stromal cells
(BMSC) as an antitumor strategy in this disease [7]. The
cellular compartment is composed of hematopoietic cells
and nonhematopoietic cells including ﬁbroblasts/BMSC,
endothelialcells(ECs),osteoclasts,andosteoblasts.Thenon-
cellularcompartmentiscomposedoftheextracellularmatrix
(ECM) and the liquid milieu including cytokines, growth
factors, and chemokines. MM cells home to the BM and
adhere to ECM proteins and to BMSC. This traﬃcking
(homing-egress) allows the progression or “metastasis” of
the disease to new BM sites [7]. However the new host
microenvironment is not well adapted to the cancer cells
that metastasized into it, leading to the new concept of
premetastatic niche [8]. Indeed signiﬁcant changes occur in
themicroenvironmentevenbeforetheﬁrsttumorcellhomes2 Journal of Biomedicine and Biotechnology
to the bone marrow, as already described in solid tumor
models [8]. In this paper, we discuss how BM may support
MM cell growth and disease progression.
2. The Bone Marrow Microenvironment
2.1. Cellular Compartment
2.1.1. Bone Marrow Stromal Cells (BMSCs) in MM Progres-
sion. MM cells adhere to BMSC and ECM into the BM.
Tumor cells bind to ECM proteins, such as type I collagen
and ﬁbronectin via syndecan 1 and very late antigen 4
(VLA-4) on MM cells and to BMSC VCAM-1 via VLA-4 on
MM cells. Adhesion of tumor cells to BMSC activates many
pathways resulting in upregulation of cell cycle regulating
proteins and antiapoptotic proteins [9]. Speciﬁcally, the
interaction between MM cells and BMSCs triggers NF-
κB signaling pathway and interleukin-6 (IL-6) secretion
in BMSCs. In turn, IL-6 enhances the production and
secretion of VEGF by MM cells. The existence of this
paracrine loop optimizes the BM milieu for MM tumor cell
growth [10]. BMSC-MM cell interaction is also mediated
through Notch. The interaction Notch-Notch ligand leads
to activating Notch-signaling pathways both in MM cells
as well as in BMSC, with induction of IL-6, vascular
endothelial growth factor (VEGF), and insulin-like growth
factor (IGF-1) secretion and is associated with MM cell pro-
liferation and survival [11, 12]. Moreover, BMSC from MM
patients expresses several proangiogenic molecules, such as
VEGF, basic-ﬁbroblast growth factor (bFGF), angiopoietin 1
(Ang-1), transforming growth factor (TGF)-β, platelet-
derived growth factor (PDGF), hepatocyte growth factor
(HGF), interleukin-1 (IL-1) [13]. Recently, BMSCs from
MM patients have been shown to release exosomes, which
are transferred to MM cells, thereby resulting in modulation
of tumor growth in vivo, mediated by speciﬁc miRNA.
This ﬁnding suggest that exosomes might constitute a novel
mechanism for intercellular transfer of genetic information
in the form of miRNA in clonal plasma cell disorders [14].
2.1.2. Endothelial Cells and Angiogenesis in MM Progression.
BM angiogenesis represents a constant hallmark of MM pro-
gression,partlydrivenbyreleaseofpro-angiogeniccytokines
from the tumor plasma cells, BMSC, and osteoclasts, such
as VEGF, bFGF, and metalloproteinases (MMPs). Indeed,
the adhesion between MM cells and BMSCs upregulates
manycytokineswithangiogenic activity, mostnotablyVEGF
and bFGF [15]. In MM cells, these pro-angiogenic factors
may also be produced constitutively as a result of oncogene
activation and/or genetic mutations [16]. Evidence for the
importance of angiogenesis in the pathogenesis of MM was
obtainedfromBMsamplesfromMMpatients[17].Thelevel
of BM angiogenesis, as assessed by grading and/or microves-
sel density (MVD), is consistently increased in patients with
active MM as compared to those with inactive disease or
MGUS, a less advanced plasma cell disorder. Comparative
gene expression proﬁling of multiple myeloma endothelial
cells and MGUS endothelial cells has been performed in
order to determine a genetic signature and to identify
vascular mechanisms governing the malignant progression
[18].Twenty-twogeneswerefounddiﬀerentiallyexpressedat
relatively high stringency in MM endothelial cells compared
withMGUSendothelialcells.Functionalannotationrevealed
a role of these genes in the regulation of ECM formation and
bone remodelling, cell adhesion, chemotaxis, angiogenesis,
resistancetoapoptosis,andcell-cycleregulation.Thedistinct
endothelial cell gene expression proﬁles and vascular phe-
notypes detected in this study may inﬂuence remodelling of
the bone marrow microenvironment in patients with active
multiple myeloma. Overall, these evidences suggest that EC
presents with functional, genetic, and morphologic features
indicating their ability to induce BM neovascularization,
resulting in MM cells growth, and disease progression,
providing preclinical evidences for using antiangiogenic
compounds in the treatment of MM.
2.1.3. Osteoclasts in MM Progression. The usual balance
between bone resorption and new bone formation is lost in
many cases of MM, resulting in bone destruction and the
development of osteolytic lesions [19]. Bone destruction
develops adjacent to MM cells, yet not in areas of normal
bone marrow. There are several factors implicated in
osteoclast activation, including receptor activator of NF-κB
ligand (RANKL), macrophage inﬂammatory protein-1a
(MIP-1a), interleukin-3 (IL-3), and IL-6 [20]. RANK ligand
is a member of the tumor necrosis factor (TNF) family
and plays a major role in the increased osteoclastogenesis
implicated in MM bone disease. RANK is a transmembrane
signaling receptor expressed by osteoclast cells. MM cell
binding to neighboring BMSC within the bone marrow
results in increased RANKL expression. This leads to an
increase in osteoclast activity through the binding of RANKL
to its receptor, on osteoclast precursor cells, which further
promotes their diﬀerentiation through NF-κB and JunN-
terminal kinase pathway [21]. RANKL is also involved in
inhibition of osteoclast apoptosis. Blocking RANKL with
soluble form of RANK has been shown to modulate not only
bone loss but also tumor burden in MM in vivo models [22].
Moreover osteoclasts constitutively secrete proangiogenic
factors osteopontin that enhanced vascular tubule formation
[23].
2.1.4. Osteoblasts in MM Progression. It has been reported
that osteoblasts may contribute to MM pathogenesis by
supporting MM cells growth and survival [24]. This could
potentially result from the ability of osteoblasts to secrete
IL-6 in coculture system with MM cells, thus increasing
IL-6 levels within the BM milieu and therefore inducing
MM plasma cells growth. Other mechanisms include
the possible role of osteoblasts in stimulating MM cells
survival by blocking TRAIL-mediated programmed MM
cell death, by secreting osteoprotegerin (OPG), a receptor
for both RANKL and TRAIL [25]. In addition, it is clear
that suppression of osteoblast activity is responsible for both
bone destructive process and progression of myeloma tumor
burden. Several factors are responsible for suppression of
osteoblast activity in MM such as DKK1 [26]. DKK1 is
a Wnt-signaling antagonist secreted by MM cells and itJournal of Biomedicine and Biotechnology 3
inhibits osteoblast diﬀerentiation. DKK1 is signiﬁcantly
overexpressed in patients with MM who present with
lytic bone lesions. Myeloma-derived DKK1 also disrupts
Wnt-regulated OPG and RANKL production by osteoblasts.
Studies have shown that blocking DKK1 and activating Wnt
signaling prevents bone disease in MM but is also associated
with a reduction in tumor burden [27–29].
2.2. Noncellular Compartment
2.2.1. Interleukin-6 in MM Progression. IL-6 is a key growth
and survival factor in MM [30]. IL-6 is primarily produced
by BMSC and osteoblasts and mediates paracrine MM
cell growth and is also secreted by MM tumor cells in
an autocrine manner [31]. IL-6 secretion from BMSC is
upregulated by many molecules/cytokines (i.e., CD40, TNF-
α,V E G F ,I L - 1 β,T G F - β) and MM cell adherence. IL-1β
appears to be one of the major cytokines responsible for the
paracrine production of IL-6 by the BMSC. The aberrant
productionofIL-1βbytheMMcellsinducesIL-6production
by BMSC, which in turn supports the growth and survival of
the myeloma cells [32]. Importantly, NF-κBp l a y sac e n t r a l
role in cytokine- and adhesion-mediated IL-6 upregulation,
and speciﬁc inhibition of NF-κB blocks IL-6 secretion [33].
After binding with its receptor, IL-6 triggers activation of
MEK/MAPK, JAK/STAT3, and PI3K/Akt signaling pathways
[34]. IL-6 induces proliferation of the tumor plasma cells
by activating the RAS/Raf/MEK-ERK signaling pathway. IL-
6 is also able to inhibit the antiproliferation eﬀects of
cyclin-dependent kinase (CDK) inhibitors p21 and p27
through the PI3K/Akt pathway [31]. IL-6 activation of the
JAK/STAT3 pathway induces tumor cells survival by up-
regulation/activation of anti-apoptotic proteins Mcl-1 and
Bcl-XL and c-Myc. Clinically, elevated serum IL-6 levels are
associated with a poor prognosis and reﬂect the proliferation
fraction of MM cells within patients [35]. Otherwise IL-1
receptor targeted therapies have shown activity in increasing
PFS of patients with smoldering disease [36].
2.2.2. Insulin-Like Growth Factor 1 in MM Progression. Insu-
lin-like growth factor 1 (IGF-1) is involved in tumorigenesis
of several solid cancers [37]. In MM, IGF-1 is secreted by
the BMSC and osteoblasts and induces growth, survival,
and migration of MM cells. The phosphorylation of IGF-1
receptor (IGF-1R), after IGF-1 binding, leads to activation
of MAPK and PI3K/Akt signaling pathway [38]. Activation
of Akt leads to activating the anti-apoptotic proteins Bcl-
XL, Bcl-2 and downregulating the proapoptotic protein Bim,
thereby promoting cell survival. IGF-1 is also well known for
its metabolic eﬀects. Interestingly, IGF-1 could be involved
in the pathophysiology that relates obesity and diabetes to
neoplasia [37].
2.2.3. Vascular Endothelial Growth Factor (VEGF) in MM
Progression. VEGF represents a well-known proangiogenic
factor: its levels increase in several hematologic malignancies
including MM [15]. I nM M ,V E G Fi sp r o d u c e db o t hb yM M
cells and BMSC, and its secretion is stimulated by diﬀerent
cytokines and cell growth factors such as IL-6, bFGF, TGF-
β or tumor necrosis factor (TNF)-α.I ti sa ni m p o r t a n t
factor in the formation of new vasculature; upon binding
with VEGF receptor-1 and -2 (VEGFR-1 and VEGFR-2), it
triggersproliferation,migration,diﬀerentiation,andsurvival
of BMSC and EC, through several signaling pathway such as
Ras GAP, FAK, PI3K/Akt, MEK/ERK, and STAT [15]. Blood
vessels are required for tumor growth and progression for
provision of vital oxygen and nutrients. It has been shown
that increased microvessel density (MVD) in BM of MM
patients is associated with poor prognosis.
3.Homing andEgress
The initiation of MM is likely from long-lived plasma cells
that develop in germinal center of lymphoid tissues and
home to the BM. Oncogenic events along with support
of the microenvironment allow the growth, survival, and
proliferation of these cells in the initial sites of the BM
niche [7]. Furthermore, some studies showed the presence
of a small number of circulating plasma cells in MM and
its association with a poor prognosis [39]. Migration of
cells through the blood to the bone marrow niches requires
active navigation, a process termed homing. The ﬁrst step
in the homing process is the rolling of the MM cell along
the EC through selectin. The adhesion and extravasation
are induced by activation of integrin—expressed by MM
cell—such as LFA-1 and VLA-4 [40]. The SDF-1/CXCR4
axis plays a critical role in homing of MM cells to the BM.
Studies to identify expression of chemokine receptors in MM
have shown large variations in CXCR4 expression ranging
from 10 to 100%. SDF-1 induces migration of MM cells in
vitro and homing into the bone marrow in vivo.M o r e o v e r ,
CXCR4knockdownledtosigniﬁcantinhibitionofmigration
to SDF-1 in MM cell lines and primary CD138+ cells [41].
MM is characterized by the disseminated involvement of the
BM, and its progression involves a continuous circulation
of the MM cells in the peripheral blood and homing back
to the BM. Mobilization or egress of cells out of the
bone marrow could be enhanced by disrupting the SDF-
1/CXCR4 axis. This may occur by decreasing SDF-1 by
proteaseintheBMmilieu[42],orbyupregulationofCXCR4
expression by hypoxia. Indeed, the bone marrow niche is
quite hypoxic (1%-2% O2)[ 43]. It has also been shown that
hypoxia leads to inactivation of E-cadherin and activation
of transcription factors regulating epithelial-mesenchymal
transition, including Snail and Twist, indicating that this
mechanism can participate to the egress process.
4.PremetastaticNiche
Although preparation of the premetastatic niche has not
been studied in MM, several works have shown the impor-
tance of the premetastatic niche in solid cancer metastasis to
the bone marrow. Indeed, the new host microenvironment is
not well adapted to the cancer cells that metastasized into it
[8]. Therefore, signiﬁcant changes in the stroma, endothelial
cells, ECM constituents, cytokines, and chemokines need4 Journal of Biomedicine and Biotechnology
to occur to allow for the growth and survival of these
metastastic cells. Preparation of the metastatic niche occurs
even before the ﬁrst metastastic cell arrives. Evidence has
emerged that growth factors and cytokines secreted by the
tumor prepare tissues for tumor cell engraftment [44].
For example, bone marrow-derived hematopoietic cells that
express VEGFR1 as the ﬁbronectin receptor VLA-4 are local-
izedtothepremetastaticsitesbeforethearrivaloftumorcells
[44]. Moreover, microvesicles such as exosomes have been
shown to alter the premetastatic niche in diﬀerent studies
[45]. Exosomes are small vesicles (30–100nm) of endocytic
origin, which are released in the extracellular milieu by
several cell types. Previous studies have shown the intriguing
role of exosomes in tumor progression. Recently, melanoma-
derived exosomes have been shown to induce neoangiogene-
sis at pre-metastatic niche sites. RAB1A, RAB5B, RAB7, and
RAB27A, regulators of membrane traﬃcking and exosome
formation, are highly expressed in melanoma cells. Rab27A
RNAinterferencedecreasedexosomeproduction,preventing
bone marrow education and reducing, tumor growth and
metastasis. These data show that exosome production,
transfer and education of bone marrow cells support tumor
growth and progression to the bone marrow [46].
5. Conclusion
Several reports have clearly indicated that MM pathophysi-
ology is supported by a strong interaction between the clonal
plasma cells and the surrounding bone marrow microen-
vironment; indeed, there are several autocrine or paracrine
circuits of growth that support the transformation from an
MGUS stage to an active MM stage. By understanding the
interaction occurring between BMSC and MM cells, and
vice versa, we have now available the preclinical rational
for testing novel therapeutical approaches in order to better
target not only the MM cell clone, but also the BM milieu,
thus preventing MM disease progression.
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